IDH1 R132L — covered by IDH1-mut label.
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-IDH1-R132L-AML |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-AML |
| Sources | SRC-CIVIC SRC-NCCN-AML-2025 |
Actionability Facts
| Biomarker | BIO-IDH-MUTATION |
|---|---|
| Variant | IDH1 R132L |
| Disease | DIS-AML |
| ESCAT tier | IA |
| Recommended combinations | ivosidenib, olutasidenib |
| Evidence summary | IDH1 R132L — covered by IDH1-mut label. |
Notes
ESCAT IA. Differentiation syndrome class AE — prophylactic dexamethasone protocol per ELN. Companion dx: Abbott RealTime IDH1.
Used By
No reverse references found in the YAML corpus.